Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy
- 30 August 2019
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 38 (6) , 1509-1515
Abstract
Purpose To evaluate the diagnostic accuracy of a second look narrow-band imaging (NBI) cystoscopy in the follow-up of patients with NMIBC as compared to a second white light cystoscopy (WLI). Patients and methods From August 2013 to October 2014, 600 patients with history of non-muscle invasive bladder cancer (NMIBC), who presented for follow-up cystoscopy at an academic outpatient clinic, were randomized to flexible WLI-cystoscopy plus second look NBI-cystoscopy (n = 300) or flexible WLI-cystoscopy plus second look WLI-cystoscopy (n = 300) in the same session. We analysed the detection rate of bladder tumours in second look cystoscopy as primary endpoint. In addition, we evaluated recurrence rates before study enrolment and after transurethral resection (TUR-BT) in each group. Results In 600 patients with a history of NMIBC, 78 out of 300 patients (26%) with WLI–NBI-cystoscopy and 70 out of 300 patients (23%) with WLI–WLI-cystoscopy were diagnosed with cancer recurrence (p = 0.507). Overall, WLI–NBI detected 404 and WLI–WLI 234 lesions, respectively. The second look cystoscopy detected 57 additional cancer lesions: 45 tumours in 18 patients with WLI–NBI and 12 tumours in 9 patients with WLI–WLI (p = 0.035). After initial examination without tumour detection an improvement was determined by the second cystoscopy in 3 patients (75 vs. 78 pat.) with WLI–NBI and in only one patient (69 vs. 70 pat.) with WLI–WLI (p = 0.137). Second look cystoscopy did not influence the detection of carcinoma in situ in both groups (p = 0.120). After TUR-BT the median recurrence-free survival was 4 months in 57 recurring patients (73%) in the group with WLI–NBI- and 6 months in 56 patients (80%) with WLI–WLI-cystoscopy (p = 0.373), respectively. Conclusion Our study showed no differences in per-patient tumour detection between WLI and NBI. Although NBI has significant benefits for detecting individual lesions overlooked by WLI-cystoscopy, this did not positively affect recurrence-free survival after transurethral resection.Keywords
Funding Information
- Olympus (1)
This publication has 31 references indexed in Scilit:
- Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk scorePLOS ONE, 2019
- Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring systemWorld Journal of Urology, 2018
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016European Urology, 2017
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Hexyl Aminolevulinate–Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non–Muscle-invasive Bladder Cancer: A Critical Review of the Current LiteratureEuropean Urology, 2013
- Bladder cancerCurrent Opinion in Oncology, 2011
- Photodynamic Diagnosis in Urology: State-of-the-ArtEuropean Urology, 2008
- The role of hexaminolevulinate fluorescence cystoscopy in bladder cancerNature Reviews Endocrinology, 2007
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- 5‐aminolaevulinic acid‐induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancerBJU International, 2005